十二烷基硫酸钠诱导银屑病动物模型的建立

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To establish a simple, rapid psoriasis model. Methods 10% SDS was applied to the skin of test group ,while distilled water was applied to the skin of control group. Results After 10% SDS was applied for 7 d, psoriasis symptoms were produced on skin of test mice such as skin thickening, swelling and subcutaneous vascular proliferation, etc. Pathology detected hyperkeratosis and corneous layer thickening, visible blood capillary dilation and congestion in the dermis and subcutaneous layer of test mice skin, compared with control mice skin. Western blotting results showed expressions of PKC β, IL - 1 β, TNF alpha, and IL - 23 were upregulated. The results above showed that the SDS-induced mouse model could reflect the some characteristics of psoriasis. Conclusions A simple, rapid psoriasis animal model is established using 10% SDS.

Key words： psoriasis animal model SDS

Received: 07 December 2012

ZTFLH:

R332

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Haijing
	ZHOU Wanqi
	ZHANG Yi
	JIN Jing
	and CHEN Xiaoguang.

Cite this article:

ZHANG Haijing,ZHOU Wanqi,ZHANG Yi等. Establishment of a psoriasis animal model using SDS[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2013, 24(5): 373-375.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2013/V24/I5/373

[1]	Bowcock A M, Cookson W O. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis[J]. Hum Mol Genet , 2004,13 (1):43-55.
[1]	Bowcock A M, Cookson W O. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis[J]. Hum Mol Genet , 2004,13 (1):43-55.
[2]	Mak R K, Hundhausen C, Nestle F O. Progress in understanding the immunopathogenesis of psoriasis[J]. Actas Dermosifiliogr, 2009,100:2-13.
[2]	Mak R K, Hundhausen C, Nestle F O. Progress in understanding the immunopathogenesis of psoriasis[J]. Actas Dermosifiliogr, 2009,100:2-13.
[3]	Martínez-Santamaría L, Guerrero-Aspizua S, Del Río M.Skin bioengineering: preclinical and clinical applications [J].Actas Dermosifiliogr, 2012,103(1):5-11.
[3]	Martínez-Santamaría L, Guerrero-Aspizua S, Del Río M.Skin bioengineering: preclinical and clinical applications [J].Actas Dermosifiliogr, 2012,103(1):5-11.
[4]	Wagner E F, Schonthaler H B, Guinea-Viniegra J, et al. Psoriasis: what we have learned from mouse models[J]. Nat Rev Rheumatol, 2010,6(12):704-714.
[4]	Wagner E F, Schonthaler H B, Guinea-Viniegra J, et al. Psoriasis: what we have learned from mouse models[J]. Nat Rev Rheumatol, 2010,6(12):704-714.
[5]	Danilenko D M. Review paper: preclinical models of psoriasis [J]. Vet Pathol, 2008, 45(4):563-575.
[5]	Danilenko D M. Review paper: preclinical models of psoriasis [J]. Vet Pathol, 2008, 45(4):563-575.
[6]	Schön M P. Animal models of psoriasis: a critical appraisal[J].Exp Dermatol, 2008,17(8):703-712.
[6]	Schön M P. Animal models of psoriasis: a critical appraisal[J].Exp Dermatol, 2008,17(8):703-712.
[7]	De Smedt A C, Van Den Heuvel R L, Zwi Berneman N,et al.Modulation of phenotype, cytokine production and stimulatory function of CD34+-derived DC by NiCl(2) and SDS[J].Toxicol In Vitro, 2001,15(4-5):319-325.
[7]	De Smedt A C, Van Den Heuvel R L, Zwi Berneman N,et al.Modulation of phenotype, cytokine production and stimulatory function of CD34+-derived DC by NiCl(2) and SDS[J].Toxicol In Vitro, 2001,15(4-5):319-325.
[8]	Rougier N, Redziniak G, Mougin D, et al. In vitro evaluation of the sensitization potential of weak contact allergens using langerhans-like dendritic cells and autologous T cells[J].Toxicology, 2000, 145(1):73-82.
[8]	Rougier N, Redziniak G, Mougin D, et al. In vitro evaluation of the sensitization potential of weak contact allergens using langerhans-like dendritic cells and autologous T cells[J].Toxicology, 2000, 145(1):73-82.
[9]	Rachael A C, Kupper T S. Misbehaving macrophages in the pathogenesis of psoriasis[J]. J Clin Invest, 2006, 116(8): 2084-2087.
[9]	Rachael A C, Kupper T S. Misbehaving macrophages in the pathogenesis of psoriasis[J]. J Clin Invest, 2006, 116(8): 2084-2087.
[10]	Van de, Kerkhof P C. The evolution of the psoriatic lesion[J].Br J Dermatol, 2007,157(1):4-15.
[10]	Van de, Kerkhof P C. The evolution of the psoriatic lesion[J].Br J Dermatol, 2007,157(1):4-15.
[11]	Mabuchi T, Chang T W, Quinter S, et al. Chemokine receptors in the pathogenesis and therapy of psoriasis[J].J Dermatol Sci, 2012, 65(1):4-11.
[11]	Mabuchi T, Chang T W, Quinter S, et al. Chemokine receptors in the pathogenesis and therapy of psoriasis[J].J Dermatol Sci, 2012, 65(1):4-11.
[12]	Ayroldi E, Bastianelli A, Cannarile L, et al. A pathogenetic approach to autoimmune skin disease therapy: psoriasis and biological drugs, unresolved issues, and future directions [J].Curr Pharm Des, 2011,17(29):3176-3190.
[12]	Ayroldi E, Bastianelli A, Cannarile L, et al. A pathogenetic approach to autoimmune skin disease therapy: psoriasis and biological drugs, unresolved issues, and future directions [J].Curr Pharm Des, 2011,17(29):3176-3190.
[13]	Rozieres A, Hennino A, Nicolas J F. TNF alpha in the physiopathology of psoriasis[J].Ann Dermatol Venereol, 2006,133(2):174-180.
[13]	Rozieres A, Hennino A, Nicolas J F. TNF alpha in the physiopathology of psoriasis[J].Ann Dermatol Venereol, 2006,133(2):174-180.
[14]	Maioli E, Valacchi G.Rottlerin: bases for a possible usage in psoriasis[J]. Curr Drug Metab, 2010,11(5):425-430.
[14]	Maioli E, Valacchi G.Rottlerin: bases for a possible usage in psoriasis[J]. Curr Drug Metab, 2010,11(5):425-430.
[15]	Manicassamy S.Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis[J]. Curr Opin Investig Drugs, 2009,10(11): 1225-1235.
[15]	Manicassamy S.Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis[J]. Curr Opin Investig Drugs, 2009,10(11): 1225-1235.
[16]	Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk[J]. J Clin Invest, 2012,122(11):3965-3976.
[16]	Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk[J]. J Clin Invest, 2012,122(11):3965-3976.
[17]	Johnson-Huang L M, McNutt N S, Krueger J G, et al.Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases[J].J Clin Immunol, 2009,29(3):247-256.
[17]	Johnson-Huang L M, McNutt N S, Krueger J G, et al.Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases[J].J Clin Immunol, 2009,29(3):247-256.
[18]	Zaba L C, Fuentes D J, Eungdamrong N J, et al.Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells[J].J Invest Dermatol, 2009,129(1):79-88.
[18]	Zaba L C, Fuentes D J, Eungdamrong N J, et al.Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells[J].J Invest Dermatol, 2009,129(1):79-88.